There is no single “best” anxiety medication for all dementia patients, but citalopram and sertraline are the most widely supported options, with citalopram showing the strongest evidence for both effectiveness and tolerability. The right choice depends on the type of dementia, other medications the person is taking, and which side effects pose the greatest risk. Before any medication is started, non-drug approaches should be tried first, as they have measurable benefits and carry no risk of the dangerous interactions that make prescribing for this population so tricky.
Why Non-Drug Approaches Come First
Clinical guidelines consistently recommend that medication for anxiety in dementia be reserved for severe cases where the person is in significant distress or at risk of harm. This isn’t a formality. A meta-analysis of non-drug interventions found that several approaches meaningfully reduce anxiety in people living with dementia. Music therapy had the largest effect, nearly twice as powerful as any other single intervention studied. Gentle physical approaches like massage and movement-based activities also reduced anxiety, as did structured programs combining cognitive and physical activities.
In practical terms, this means establishing a calm, predictable daily routine, reducing noise and overstimulation, using familiar music, and ensuring the person is not in unrecognized pain. Pain is a common and overlooked driver of anxiety and agitation in dementia. Simple analgesics like acetaminophen are actually recommended as a first-line intervention for behavioral symptoms when undetected pain may be a factor. If these steps don’t bring adequate relief, medication becomes a reasonable next step.
Citalopram: The Strongest Evidence
Among all antidepressants studied for agitation and anxiety in dementia, citalopram is the only one that has consistently shown statistically significant improvement over placebo while maintaining a safety profile comparable to placebo in clinical trials. A landmark trial in patients with Alzheimer’s disease found that 30 mg daily improved behavioral symptoms and agitation scores in patients who were not depressed, suggesting the benefit is specific to anxiety and agitation rather than just a side effect of treating depression.
Citalopram belongs to the SSRI class, which works by increasing the availability of serotonin in the brain. SSRIs are generally better tolerated in older adults than older antidepressant classes, but they are not without risks. About 9% of older adults taking an SSRI develop low sodium levels, a condition called hyponatremia. That number rises to around 13% if the person is also taking a common type of blood pressure medication (thiazide diuretics). Symptoms of low sodium include confusion, nausea, headache, and in severe cases, seizures. Sodium levels are typically checked within the first few weeks of starting treatment.
One important limitation: SSRIs take 4 to 6 weeks to reach full effect. Caregivers should not expect rapid improvement. The medication gradually shifts how the brain processes emotional information, which is why the timeline is measured in weeks rather than days.
Sertraline and Escitalopram as Alternatives
Sertraline has also demonstrated efficacy for agitation in dementia and is better tolerated than antipsychotic medications. It is typically started at 50 mg daily and may be increased up to 100 or 200 mg depending on response. It’s a reasonable alternative when citalopram isn’t suitable, though the evidence supporting it is slightly less robust.
Escitalopram, a closely related compound to citalopram, has been studied at doses around 15 mg daily. It may offer similar benefits with potentially fewer drug interactions, making it useful for patients on multiple medications. Both share the same general side effect profile as citalopram, including the risk of low sodium and the 4-to-6-week onset period.
Buspirone for Patients Who Can’t Take SSRIs
Buspirone is sometimes used when SSRIs are not an option. It works through a different mechanism and does not carry the same risk of low sodium or the sedation associated with some other anxiety medications. In a retrospective study of 179 dementia patients treated with an average dose of about 26 mg daily, 68% showed improvement on a standard clinical rating scale. The typical dosing range is 15 to 60 mg per day, split into multiple doses.
The evidence for buspirone is weaker than for citalopram, based on observational data rather than randomized controlled trials. But its favorable side effect profile makes it a practical choice for certain patients, particularly those who have had problems with SSRIs or who take medications that interact with them.
Mirtazapine When Sleep and Weight Loss Are Factors
Mirtazapine occupies a specific niche. It has mild sedating properties and stimulates appetite, which makes it particularly useful for dementia patients who are losing weight, sleeping poorly, or both. It is typically started at 7.5 mg at bedtime and can be increased to a maximum of 30 mg daily.
The evidence for mirtazapine’s effect on anxiety and agitation in dementia comes mainly from secondary analyses rather than dedicated trials. It is not a first-line choice for anxiety alone, but when anxiety coexists with insomnia and poor nutrition, it can address multiple problems with a single medication.
Why Benzodiazepines Are Risky
Benzodiazepines (medications like lorazepam and diazepam) are commonly prescribed for anxiety in the general population, and many caregivers wonder why they aren’t used more often in dementia. The short answer is that the risks are disproportionately high in this group. Benzodiazepines increase the risk of falls, cause excessive sedation, and worsen confusion. In a large community-based study of over 1,900 adults aged 65 and older, benzodiazepine use was significantly associated with developing mild cognitive impairment, suggesting these drugs may accelerate the very decline caregivers are trying to manage.
There are narrow situations where a short-acting benzodiazepine might be used briefly for acute, severe distress, but routine or ongoing use is discouraged by virtually every major guideline.
The Antipsychotic Warning
Antipsychotic medications are sometimes prescribed for severe agitation when other options have failed, but they carry an FDA black box warning for use in elderly dementia patients. Across 17 controlled studies, patients treated with antipsychotics were 1.6 to 1.7 times more likely to die than those given placebo. The FDA warning explicitly states that these drugs are not approved for behavioral symptoms in elderly patients with dementia. When anxiety is the primary symptom rather than psychosis, antipsychotics are rarely justified as a starting point.
Special Risks in Lewy Body Dementia
If the person has Lewy body dementia (or Parkinson’s disease dementia), medication choices narrow considerably. This type of dementia involves significant disruption to the brain’s chemical signaling systems, making patients dangerously sensitive to certain drugs that are tolerated in Alzheimer’s disease.
Antipsychotics are especially hazardous here. Between 30% and 50% of Lewy body dementia patients experience severe sensitivity reactions to antipsychotic medications, including extreme rigidity, dangerous drops in blood pressure, prolonged unresponsiveness, and sometimes death. These reactions can occur after a single dose. Haloperidol, olanzapine, and risperidone should be avoided entirely. Despite these known dangers, antipsychotics are prescribed more frequently in Lewy body dementia than in Alzheimer’s, a troubling pattern that caregivers should be aware of.
Older antidepressants called tricyclics are also problematic in Lewy body dementia. While they have some evidence for mood symptoms, their anticholinergic properties worsen cognitive function, cause constipation, and drop blood pressure in patients whose brain chemistry is already compromised. Any medication with anticholinergic effects, including common bladder medications and certain over-the-counter sleep aids, should be used with extreme caution or avoided. SSRIs like citalopram and sertraline remain the safer options for this group.
Gabapentin as a Last Resort
Gabapentin and pregabalin have been used when standard treatments fail or carry too many risks, but the evidence is thin. No randomized controlled trials have been completed. The available data comes entirely from case series and retrospective reviews, the lowest tier of clinical evidence. Doses used in case reports range widely, from 200 mg to 3,600 mg daily for gabapentin.
Current guidance is clear: these medications should only be considered after SSRIs, and potentially antipsychotics or other agents with stronger evidence, have either failed or been ruled out due to side effects or interactions.
What Caregivers Should Watch For
Whichever medication is chosen, the first few weeks require close observation. With SSRIs, watch for increased confusion, nausea, unsteadiness, and signs of low sodium (which can look like worsening dementia). The therapeutic effect typically takes 4 to 6 weeks, so a medication that seems unhelpful at week two may simply need more time. If side effects appear severe or the person’s function noticeably declines, that warrants a call to their prescriber rather than waiting out the full trial period.
Because dementia patients often cannot clearly report how they feel, caregivers become the primary source of information about whether a medication is working. Keeping a simple daily log of anxiety episodes, sleep quality, appetite, and any new behaviors gives the prescriber concrete data to work with, rather than relying on impressions from brief clinic visits.